PolyPid has been granted an extension to regain compliance with Nasdaq's minimum bid requirement, which may provide the company with additional time to improve its stock price. However, the short-term impact on the stock price is uncertain, as the company still needs to regain compliance. The transfer to the Nasdaq Capital Market may also have a neutral impact, as it does not directly affect the company's fundamentals.